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Escherichia (E.) coli K1 strains remain common causative agents of neonatal sepsis and meningitis. We have isolated a lytic
bacteriophage (ΦIK1) against E. coli strain IHE3034 and tested its specificity in vitro, as well as distribution and protective efficacy
in vivo. The phage was shown to be specific to the K1 capsular polysaccharide. In the lethal murine model, a high level of
protection was afforded by the phage with strict kinetics. A single dose of 1 x 108 phage particles administered 10 and 60 minutes
following the bacterial challenge elicited 100 % and 95 % survival, respectively. No mice could be rescued if phage administration
occurred 3 hours postinfection. Tissue distribution surveys in the surviving mice revealed that the spleen was the primary organ
in which accumulation of active ΦIK1 phages could be detected two weeks after phage administration. These results suggest that
bacteriophages have potential as therapeutic agents in the control of systemic infections.
1. Introduction
Thenumber of bacterial septicemia cases has been on the rise
worldwide, affecting more than a million Americans [1], of
whom between 28 and 50 % die [2].
After entering the body, survival and outcome of the
hematogenous spread partially depends on the fitness and
virulence factors of the invader. Certain factors enable
bacteria to enter the central nervous system (CNS) and
cause meningitis. The K1 serotype of Escherichia (E.) coli
is the leading causative agent of Gram-negative bacterial
meningitis with significant mortality and morbidity in new-
borns worldwide [3]. Its pathogenesis and pathophysiology
have been investigated mostly using two E. coli K1 isolates
originally isolated from the cerebrospinal fluid (CSF) of
neonates with sepsis and meningitis [4]. Serotypes of these
strains (RS218 and IHE3034) are identical, O18:K1:H7 [4].The
K1 capsule identical to the capsule of Neisseria meningitides
B is thought to be one of the most important virulence
factors as it supports survival in the host [5]. No vaccination
is available for this capsule type because of the molecular
mimicry between the serogroup B capsule and the tissue
antigen of neuron cell adhesion molecule [6].
Capsule is not only a virulence associated factor, but a
dominant outer surface cellular structure that is an ideal tar-
get for bacteriophages. These viruses can infect and multiply
inside the bacterial host and, due to their specificity, they
can be used to reduce target bacteria. Recently phage therapy
has regained general interest as resistance to antibiotics has
become a serious problem [7], and phage therapy has been
found to be effective in treating many bacterial infections.
Recent animal experiments have demonstrated the potential
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of phages as alternative therapeutic agents in various infec-
tion models ranging from topical wound and burn infections
[8–10], pneumonia [11], and lung- [12] and intra-abdominal
[13, 14] bacteremic infections.
In this work, we isolated a lytic bacteriophage specific
for the K1 capsule of the newborn meningitis E. coli strain
IHE3034 and demonstrated its therapeutic efficacy in a
progressive intravenous mouse model. We demonstrated
that intravenous administration of phages could effectively
control progressive infections evoked by high bacterial cell
number.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions. The newborn
meningitis E. coli (NMEC) strain IHE3034 (O18ac:K1:H7;
phylogroup B2; sequence type ST95) was used throughout
the study. It was originally isolated by 1976 in Finland [4] and
kindly provided by the authors.
2.2. Bacteriophage Isolation. Bacteriophages against the
NMEC strain IHE3034 were isolated from raw sewage water
harvested from the Tettye Forra´sha´z Treatment Plant located
in Pe´cs-Pelle´rd, Hungary. Briefly, 5 ml sewage and 1 ml O/N
culture of IHE3034 were added to 50 ml Luria-Bertani broth
(LB) medium (Oxoid, USA) and incubated at 37∘C and
150 rpm for 24 h. The following day, 1.5 ml of the infected
LB-sewage mixture was harvested and centrifuged at 8,000 x
g for 5 min to pellet cells and debris. From the supernatant,
980 𝜇l was transferred to a 1.5 ml reagent tube and 20 𝜇l of
chloroform (Sigma, USA) was added and left at 4∘C after
shaking. After O/N incubation the sample was centrifuged
(8,000 x g for 5 min) and a 100x serial dilution series (102x,
104x, 106x, 108x) was prepared for plaque forming unit (PFU)
determination. Ten 𝜇l from each dilution step was added to
4 ml of molten top agar (0.4% agar) tempered to 54∘C and
poured onto LB agar plates (1.5% agar) previously layered
with lawns of logarithmic phase (OD
600
=0.8) culture of
IHE3034. Plates were incubated O/N at 37∘C. Phages were
stored at 4∘C, tested before use, and diluted accordingly.
2.3. Selection of Bacteriophages Specific for the K1 Capsule–K1
Mutant Construction. Phage plaques from the top agar plates
were individually isolated and propagated in the presence
of the wild-type IHE3034 NMEC strain. Tests of the phage
suspensionswere performed on the IHE3034wild-type strain
and effective phage plaques were picked up, propagated on
IHE3034 K1, and counterselected on the lawn of its isogenic
capsule mutant (ΔK1).
The capsule mutant was gained by using the Datsenko
and Wanner method [15] based on the application of
lambda Red recombinase expressing helper plasmid
pKD46. Briefly, pKD46 was first electroporated into
the wild-type IHE3034 and maintained at 30∘C in
the presence of Ampicillin (100𝜇g ml−1). PCRs were
performed by using the primer pairs IHE R2 pKDfw:
5󸀠-TGGGTTTATTATGGGGGGAACACAACAAACTGC-
CAACATAATATATATTAAATTTCAAGTCAATAT-
CTTTTGAATTTTAAGTGTAGGCTGGAGCTGCTTC,
and IHE R2-pKDrev: 5’-TTTATCTTAACAAAGAGG-
GGCAAGGTAAATTTTATAAAAATGTTACGG-
AAGCCATTGCTGATTACAAAAAAGACCTAT-
AGCATATGAATATCCTCCTTAGTTCCTATTCC from the
template plasmid pKD3 containing the cat cassette (encoding
for the chloramphenicol resistance). The PCR product was
electroporated into the freshly made competent cells of
IHE3034 containing the L-arabinose (>10 mmol) induced
lambda Red recombinase encoded on the pKD64 helper
plasmid. Selection of the mutants was carried out in the
presence of chloramphenicol. Elimination of Region2 of
the capsule locus was tested by PCR by using the primers:
kpsT IHEell: 5󸀠-CATGGCCCGTTGGATTGGC and KpsS
IHEell: 5󸀠-CAGTACGGCGGGGATCTCT. Loss of the K1
capsule was phenotypically confirmed by latex agglutination
(Thermo Fisher Scientific, USA) and designated as IHE3034
ΔK1.
Phages specific for K1 were purified three times on the
IHE3034 strain by using the standard procedure described by
Sambrook et al. [16].
2.4. Propagation and Purification of Phage Strains. High-
titer phage stocks for in vivo experimentation and sequence
analysis were propagated and amplified in the IHE3034 host
bacterium strain by standard procedures [17]. For large-scale
phage preparations for animal experiments the propagated
phage and bacterium suspensions were centrifuged (2500 x g,
5 min) and the supernatants were filtered through a 0.22 𝜇m
filter (Sarstedt, Germany), centrifuged (18000 x g, 30 min),
and resuspended in 0.1M phosphate-buffered saline (PBS).
Plaque forming units (PFUs) were determined and expressed
in PFUml−1, and stocks were stored at 4∘C.These stocks were
used for DNA isolation and subsequent sequencing.
2.5. Electron Microscopic Analysis. Morphology of phages
was investigated by transmission electron microscopy as pre-
viously described [17]. Briefly, one drop of phage suspension
was placed on copper gridswith carbon-coated Formvar films
and negatively stained with 2% ammonium molybdate (pH
6.8) for 1.5 min. The samples were examined in a Jeol 1010
transmission electron microscope (JEOL Inc. Peabody, MA
USA) operating at 80 kV.
2.6. Pyrosequencing and Bioinformatics. Phage nucleic acid
was isolated using the High Pure Viral Nucleic Acid Kit
(Roche Applied Science, Mannheim, Germany), according to
manufacturer’s instructions. The complete genome of ΦIK1
was sequenced by the shotgun full-sequencing strategy using
the GS Junior+platform (Roche Diagnostics GmbH, Ger-
many). The mean coverage of ΦIK1 was 1380. The assembly
of the sequence was performed with Geneious 8 software.
Reads were mapped against the ΦIK1 genome sequence and
the coverage was investigated for detection of direct repeats.
Open reading frames (ORFs) were predicted using RAST
[18].
2.7. In Vitro Activity Analysis of E. coli IHE3034 Treated with
ΦIK1. In vitro activity was assessed to provide a quantitative
analysis of the efficacy of the phage bactericidal activity in
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the presence of different phage-bacterium ratios. These tests
were performed in a 96-well tissue culture plate. Briefly, O/N
culture of IHE3034 was set to an OD
600
of 1 (∼2 x 108 CFU
ml−1) and the initial ΦIK1 bacteriophage suspension was set
to ∼2 x 108 PFU ml−1).
The 96-well tissue culture plate was partitioned on four
parallel sections. Each section contained 3 columns (1-3, 4-
6, 7-9, 10-12) filled with 106, 105, 104, and 103 CFU ml−1
bacterial suspensions (180𝜇l), respectively. Rows “A” and “H”
contained sterile growthmediumas a negative growth control
(Figure 2). All other rows contained 20𝜇l of bacteriophage
suspensions from the phage dilutions of 106, 105, 104, 103,
and 102. The final ΦIK1 phage concentrations were 10 times
diluted (105, 104, 103, 102, and 101 PFUs ml−1).
By using this checker board testing the following phage,
bacteriummultiplicity of infection (MOI) values were tested:
100:1; 10:1; 1:1; 1:10; 1:100; 1:1000; 1:10000; 1:100000. The assay
was run for 24 h at 37∘C.Bacterial growthwas registered every
5 min by measuring the OD of each well with a multimode
microplate reader (BioTek Synergy HT).The experiment was
performed three times.
2.8. Mutation Rate Determination of the Receptor of ΦIK1.
IHE3034 suspension (1 x 108)was evenly spread on the surface
of an LB agar plate and 10 𝜇l of the ΦIK1 suspension (1 x
108 PFU mL−1) was added dropwise. The area of the cleared
lytic zone was measured and emerged resistant colonies were
determined. Determination was performed three times.
2.9. LethalDose of IHE3034 in the Intravenous InfectionMouse
Model. For in vivo tests, 6-7-week-old female BALB/c (19-21
g) and NMRI (20-22 g) mice were purchased from Charles
River (Germany). Animals were cared for in accordance with
the guidelines of the European Federation for Laboratory
Animal Science Associations (FELASA), and all procedures,
care, and handling of the animals were approved by the
Animal Welfare Committee of University of Pe´cs.
For infection, log-phase bacteria grown in LB broth were
washed in PBS and the optical density was set to OD
600
=0.5
(∼1 x 108 CFU mL−1); OD
600
=1 (∼2 x 108 CFU mL−1);
OD
600
=5 (∼1 x 109 CFUmL−1); and OD
600
=10 (∼2 x 109 CFU
mL−1). Groups of 10 mice received intravenous doses of 100
𝜇l from the above suspensions, giving a final amount of ∼1 x
107; ∼2 x 107; ∼1 x 108; and ∼2 x 108 bacterial cells, respectively.
Death and general conditions were recorded for the following
7 days and LD50 value for IHE3034 was determined on both
mouse strains.
2.10. Therapeutic Efficacy of ΦIK1 in the Intravenous Mouse
Model. This study was performed in strict accordance with
the FELASA (Federation of European Laboratory Animal
Science Associations) guidelines and recommendations. The
animal experiments were approved by the ethical committee
of the University of Pe´cs (Permit Number: BA02/2000-
20/2011). Altogether 6 groups (6mice per group) of 6-7-week-
old female BALB/cmice (19-21 g) were used. Five groupswere
intravenously infected with 0.1 mL, OD
600
=5 (1 x 108 CFU
/ mouse), IHE3034 E. coli NMEC strain. One group served
Figure 1: Morphology of ΦIK1 shows typical characteristics of
Podoviridae. Bar represents 100nm.
as a negative or bacteriophage control (GPC), receiving
0.1 ml bacteriophage suspension (1 x 108 PFU ml−1). The
bacterial control group (GBC) received only 0.1 ml OD
600
=5
bacteria (1 x 108 CFU / mouse), while 0.1 ml bacteriophage
suspensions (1 x 108 PFU / mouse) were administered to all
other groups 10 min (G10M), 1 h (G1H), 2 h (G2H), and
3 h (G3H) postinfection. General conditions and survival
rates of the mice were permanently monitored for two weeks.
Experiments were performed twice.
2.11. Assessing the Titers of ΦIK1 in Different Organs. Two
weeks after phage therapy treatments, all mice were sacrificed
and the concentration of active bacteriophages in the blood,
brain, and spleenwas determined.Organswere homogenized
in 2.5 ml PBS with a blade stirrer for 5 seconds. Tissue
suspensions were centrifuged (8,000 x g for 5 min) and
chloroformed as described above. Ten 𝜇l from these and the
100x diluted tissue suspensions were added to a bacterial
lawn, incubated at 37∘C, and PFUs were determined the
following day. Detection limit of the test was 100 phage
particles in 1 ml blood and 250 phage particles in the brain
and spleen.
3. Results
3.1. Characterization of E. coli IHE3034 Bacteriophages Iso-
lated from Sewage Water. Ten bacteriophages specific for the
K1 capsule were purified from the local municipal sewage
treatment facility of Pe´cs-Pelle´rd. Comparison of their DNA
restriction profiles and recognition patterns on an E. coli
strain collection has suggested that the 10 isolated phages
were the same. Onewas chosen for further in vitro and in vivo
studies and called ΦIK1. Transmission electron microscopy
analysis of ΦIK1 indicates the typical characteristics of
Podoviridae with a head diameter of ∼80 nm (Figure 1.).
3.2. K1 Mutant Production from IHE3034 and Mutation
Rate Determination. No clearing zone was observed on the
capsule deficient isogenic mutant strain IHE3034 ΔK1 when
10𝜇l of ΦIK1 suspension was added to a bacteria-coated agar
plate. However, it did cause a clear plaque in the presence of
the wild-type IHE3034 E. coli K1 strain.
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Figure 2: In vitro kinetics of theΦIK1-IHE3034 interaction in different MOIs. Lines A (medium control), B (bacterium growth control), and
H (medium control) are control fields. In rows C, D, E, F, and G the final concentration of phages are 105, 104, 103, 102, and 101, respectively.
In columns 1-3, 4-6, 7-9, and 10-12 bacterial end concentrations were 106, 105, 104, and 103 respectively. Accordingly ratios are presented PFU:
CFU.
The mutation rate of the receptor of ΦIK1 was 4.1 x 104.
The K1 agglutination assay revealed that 100% (34/34) of the
tested colonies resistant to ΦIK1 lost the K1 capsule.
3.3. Sequence Analysis. Sequence analysis of ΦIK1 revealed
that the genome size of ΦIK1 was 44246 bps with 94-96
% sequence similarity to 7 previously sequenced E. coli
bacteriophages also belonging to Podoviridae. Altogether 58
ORFs of ΦIK1 were identified. The sequence of ΦIK1 was
deposited in the Genbank under the accession number:
KY435490.
3.4. In Vitro Activity Analysis. The 24 h in vitro time kill
analysis revealed that ΦIK1 could hinder the proliferation
of IHE3034. This inhibitory effect depended on the starting
CFU of IHE3034 (Figure 2). If an MOI with a phage: bac-
terium ratio of 1:10 (105:106) was applied (see row C, columns
1-3) IHE3034 could overcome the attack of bacteriophage
and by the end of the 24th hour the CFU number equaled
the positive controls (only bacterium, no phage, row B). In
contrast, ΦIK1 could successfully clear IHE3034 if at least a
1:1 bacteriophage: bacterium ratio was applied (MOIs: 104:104,
D7-9; 103:103 E10-12).
At a bacterial concentration of 105 CFU ml−1, the lytic
effect of ΦIK1 was not significant as IHE3034 culture could
avoid the inhibitory effect ofΦIK1 if the phage was diluted to
104, 103, 102, and 101 PFUml−1 (D4-6, E4-6, F4-6, G4-6).This
tendency changed if a 104 CFU mL−1 bacterium suspension
was tested in the presence of 10x, 100x, and 1000x less phage
BioMed Research International 5
0 6 12 18 24 30 36 42 48 54 60 66
0
20
40
60
80
100
Hours post challenge
Pe
rc
en
t s
ur
vi
va
l
GBC
G3H
G2H
G1H
G10M
GPC
p=0.0021
p=0.44
p<0.0001
Figure 3: In the phage rescue experiment, survival of IHE3034
infected BALB/c mice strongly depended on the elapsed time
between the injection of bacterium suspension (1 x 108 CFU/mouse)
and ΦIK1 (1 x 108 PFU / mouse). Phage administration occurred 10
min (G10M), 1 h (G1H), 2 h (G2H), and 3 h (G3H) postinfection,
while the IHE3034 and the ΦIK1 suspensions were used as positive
(GBC) and negative (GPC) controls, respectively. The obtained
survival curves were statistically compared by the logrank (Matel-
Cox) test using the GraphPad Prism 6.0 software.
particles (MOI: 1:10; 1:100 and 1:1000; see wells E7-9, F7-9 and
G7-9 respectively). In these cases the growth of bacteria was
effectively hindered by ΦIK1. This was also observed if the
bacterial cell number was further decreased to 103 CFUml−1.
This threshold at which IHE3034 could grow, at an
inoculum of 105 (Figure 2, column 4-6), is in accordance with
the mutation rate of ΦIK1 receptor (∼104).
3.5. IntravenousMouse SepsisModel of IHE 3034. Twomouse
strains were used to establish the systemic infection mouse
model for IHE3034. BALB/c mice were more sensitive to
IHE3034, as intravenous administration of 0.1 ml cell suspen-
sion (OD
600
=10) caused 100 % mortality in 24 h (SFigure 1.).
Most of the mice survived if 0.1 ml suspensions of OD
600
=0.5
(1 x 107 CFU) or OD
600
=1 (2 x 107 CFU) bacterial cells
were injected intravenously. Administration of 0.1 ml from
OD
600
=5 (1 x 108 CFUs / mouse) caused the death of all mice
in 48 h.
In contrast, no complete mortality could be achieved
in any of the NMRI mice groups treated with the above
suspensions (SFigure 1.).
3.6. Phage Rescue of the IHE3034 Rapid Sepsis by ΦIK1. The
bactericidal activity of ΦIK1 observed in vitro could be cor-
roborated in the rapid sepsis mouse model. The restraining
effect strongly depended on the time between infection and
phage administration.
All 12 positive control mice (GBC) infected with 1 x
108 CFU IHE3034 bacterium suspension died within 48 h
(Figure 3). No effect was observed when phage suspension
only (1 x 108 PFU / mouse) was administered to healthy
mice (groupof phage control, GPC). Bacteriophages exerted a
100% curing effect if administered within 60 min of bacterial
infection, saving the life of all infected mice.
Efficacy of phage treatment was drastically altered if
administration of ΦIK1 followed bacterial challenge by 2 h
(G2H). In this case, survival rate at 24 h was 91.6% (11/12),
but it drastically decreased to 33.3% (4/12) by the 48th hour
(Figure 3). Two mice survived from this group after the 60th
hour and eventually recovered after 7-10 days. No rescue
effect of ΦIK1 was detected, with a 0% survival rate at 48 h
postinfection if phage was administered 3 h after bacterial
infection.
3.7. Reisolation of Persisting ΦIK1 Phages from Different
Organs. Two weeks after bacterial challenge and subsequent
phage administrations, surviving mice were sacrificed and
active ΦIK1 phage particles were isolated from the blood,
spleen, and brain (Figure 4, x-axis). The spleen was the only
organ in which active phage particles could be detected in
a significant amount, totalling <35000 PFU / spleen. The
number of detectable phage particles was more limited in the
brain (<1750 PFU / brain) and blood (<1250 𝜇l−1) (Figure 4).
In the phage control group (GPC) no phage particles (0/12)
were detected in the brain and a limited number of phages
(<1000) were found in the blood of two sacrificed animals
(2/12).
4. Discussion
Bacterial sepsis can progress if an aetiological agent enters
the body and its hematogenous spread occurs.This condition
strikes more than a million Americans [1] and has a high
(28-50%) mortality [2]. Due to the emergence of multidrug
resistance (MDR) among the aetiological agents it is increas-
ingly obvious that new treatment options are needed [10].The
application of targeted bacteriophages could be a promising
approach.
Counterselection of isolated lytic phageswith the isogenic
receptor mutant bacteria is an effective method to isolate
targeted phages for a well-determined receptor. For this
purpose, we have constructed and used the IHE3034 ΔK1
strain and isolatedΦIK1, targeting one of the most important
virulence factors of the newborn meningitis-causing E. coli
strain IHE3034 [19, 20]. We have chosen the K1 capsule
as a target since it not only hinders opsonization [21], but
also contributes to adhesion, promoting invasion through the
blood-brain barrier (BBB) [19, 22].
Although the exact timing of the pathomechanism in
IHE3034 in mice is not known, the 100% efficacy of theΦIK1
treatment could be achieved if the phages were administered
1 h after bacterial challenge (G10M and G1H, Figure 3).There
are several possible reasons for the inefficacy of phage rescue
when performed after the first hour of infection (G2H and
G3H), including the presence of phage resistant colonies in
the inoculum. However their frequency was quite high (104
ml−1) so resistant cells would have been incapable of evoking
the pathogenic process. This is supported by the results of
the in vitro experiments where ΦIK1 controlled IHE3034
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Figure 4: Detection of active phages in the surviving mice two weeks after bacterial challenge and phage rescue. Results are subdivided
according to the organs (X axis). In each subsection (1-12) the summarized results of the GPC, G10MG1H, andG2H are presented as columns.
G3H and GBC were not drafted as no mice survived in G3H, while no phage was administered to GBC (STable 1.).
at 1:1000 MOI (Figure 2), but only when the bacterial cell
number was below 104 CFU (the mutation rate).
Still, enough K1 expressing cells were in the blood of the
experimental animals to take over a fatal pathogenic process.
In our model system, IHE3034 could only trigger a rapidly
escalating infection if the bacterium number was fairly high
(1 x 108 CFU / mouse). This is in accordance with other
experimental setups performed with Enterococcus faecium as
109 [13], Staphylococcus aureus as 108 [23], and Pseudomonas
aeruginosa as 107 [14]. Compared to these experiments the
100% efficacy (G1H) of the phage rescue in relation of ΦIK1
and IHE3034 (1:1 MOI) is comparable to results of other
studies, where 100% survival of the challenged mice were
reported if∼1:3 (3x108:1x109), 10:1 (109:108)MOIswere applied
and administration of phages occurred 45 min and 1 h after
bacterial challenges [13, 23]. Amore striking rescue effect was
reported by Wang et al. [14] where the 1:100 MOI still had
a 100% protective effect if the isolated Pseudomonas-specific
phage was administered up to 1 h after the infection. This
could be due to the fact that differences in the bacterium
species used, E. faecalis, S. aureus, P. aeruginosa, and NM
E. coli, possess different pathomechanisms. This strongly
influences the availability of the infectious agent in the host.
Bacteria that are capable of intracellular survival, such
as IHE3034 [20], can hide from bacteriophages and by this
can assure their survival and lead to pathogenesis. E. faecium
is able to survive and proliferate in murine macrophages
[24] and there is also a mounting evidence that S. aureus
has the potential to internalize and survive within host
cells [25]. In contrast P. aeruginosa is thought to be an
extracellular bacterium and therefore it is more vulnerable
to bacteriophages. Intracellular bacteria are vulnerable until
they reach, adhere to, and invade certain cells, protecting
themselves from the extracellular phages. This may explain
why phage rescue experiments were more effective with
extracellular P. aeruginosa.
This process could be influenced by the tissue penetration
potential of bacteriophages. The presence of ΦIK1 in the
spleens of animals in the phage control group (GPC), and the
surviving animals in groups G10M, G1H, and G2H, indicates
that the phage could survive in the spleen for at least 2 weeks,
until the mice were sacrificed.
Lack of ΦIK1 in the brains of the GPC group suggests
that this phage cannot penetrate the BBB under normal
conditions. However phage was detected in the brains of
groups G10M and G1H (Figure 4.). We hypothesize that
in group (G1H) ΦIK1 phages could also exert their lytic
effects in the brain, contributing to rescue. At least two
different mechanisms could be considered for this process.
It is known that, upon inflammation, the BBB can become
permeable, facilitating the transfer of macromolecules and
viruses [26]. Our study contradicts this in the case of ΦIK1
as administration of 108 heat-killed IHE3034 cells 1 h prior
to the intravenous phage administration did not result in
the detection of active phage particles in the brains of
experimental animals when sacrifice occurred 1, 3, or 7 days
after administration (unpublished data).
Based on this observation we postulate that the already
phage-infected IHE3034 cells crossed the BBB into the brain
tissue.
Phages are alternative therapeutics against multidrug
resistant bacteria, but there are still questions about their
practical use, especially in systemic infections. Besides the
immunological aspects, a good understanding of phage-
bacteria interactions and phage survival in the body is
required. Our results demonstrate that, in accordance with
previous findings, phages can not only combat bacteria
already present in the circulatory system, but also survive
in the spleen afterwards. Future work must be dedicated to
those factors that influence this and possibly enhance the
therapeutic potential of phages.
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Supplementary Materials
Supplementary figure 1 : concentration-dependent sen-
sitivity of the BALB/c (A) and CD1 (B) mice for the
IHE3034 E. coli K1 meningitis strain on a time scale. Ten-
ten mice were intravenously injected with 100 𝜇L doses of
OD
600
=0.5 (∼1 x 108 CFU mL−1); OD
600
=1 (∼2 x 108 CFU
mL−1); OD
600
=5 (∼1 x 109 CFU mL−1); and OD
600
=10 (∼
2 x 109 CFU mL−1) bacterial suspensions getting a final
amount of ∼1 x 107; ∼2 x 107; ∼1 x 108; and ∼2 x 108
bacterial cells, respectively. Death rates are represented in
both mice strains. Supplementary Table 1 : detection of
active phages particles in the different organs of the sur-
vived mice two weeks after bacterial challenge and phage
rescue / administration (Supplementary Table for Figure 4.).
(Supplementary Materials)
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